Pfizer Champix Product Recall (2021-06-08)
- Starting date:
- June 8, 2021
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type II
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-75843
Last updated:
2021-06-15
Summary
-
Product:
A. Champix 0.5 mg tabletsB. Champix 0.5 / 1.0 mg tablet kit
A. Champix 0.5 mg tablets
B. Champix 0.5 / 1.0 mg tablet kit
Reason
Presence of impurity N-nitrosovarenicline above the acceptable concentration limit in affected lot.
Depth of distribution
Retailers
Affected products
A. Champix 0.5 mg tablets
DIN, NPN, DIN-HIM
DIN 02291177
Dosage form
Tablet
Strength
Varenicline tartrate 0.5 mg
Lot or serial number
ED7397
Companies
- Recalling Firm
-
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland
H9J 2M5
Quebec
CANADA
- Marketing Authorization Holder
-
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland
H9J 2M5
Quebec
CANADA
B. Champix 0.5 / 1.0 mg tablet kit
DIN, NPN, DIN-HIM
DIN 02298309
Dosage form
Kit
Strength
Varenicline tartrate 0.5 mg
Varenicline tartrate 1.0 mg
Lot or serial number
00019062, 00020452, 00020451
Companies
- Recalling Firm
-
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland
H9J 2M5
Quebec
CANADA
- Marketing Authorization Holder
-
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland
H9J 2M5
Quebec
CANADA